Solid Biosciences (SLDB) Competitors $5.78 -0.22 (-3.67%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$6.11 +0.33 (+5.71%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SLDB vs. KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, PGEN, and STOKShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), Precigen (PGEN), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen Stoke Therapeutics Solid Biosciences (NASDAQ:SLDB) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Do analysts rate SLDB or KURA? Solid Biosciences currently has a consensus target price of $15.40, indicating a potential upside of 166.44%. Kura Oncology has a consensus target price of $27.13, indicating a potential upside of 228.95%. Given Kura Oncology's higher possible upside, analysts plainly believe Kura Oncology is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 4 Strong Buy rating(s) 3.31Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more volatility & risk, SLDB or KURA? Solid Biosciences has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Is SLDB or KURA more profitable? Kura Oncology's return on equity of -44.09% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -58.75% -47.84% Kura Oncology N/A -44.09%-39.57% Which has better valuation & earnings, SLDB or KURA? Solid Biosciences has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid Biosciences$8.09M28.99-$96.01M-$3.04-1.90Kura OncologyN/AN/A-$152.63M-$2.36-3.49 Do institutionals and insiders believe in SLDB or KURA? 81.5% of Solid Biosciences shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 5.5% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer SLDB or KURA? Kura Oncology received 156 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 69.48% of users gave Kura Oncology an outperform vote while only 69.04% of users gave Solid Biosciences an outperform vote. CompanyUnderperformOutperformSolid BiosciencesOutperform Votes27269.04% Underperform Votes12230.96% Kura OncologyOutperform Votes42869.48% Underperform Votes18830.52% Does the media prefer SLDB or KURA? In the previous week, Solid Biosciences had 16 more articles in the media than Kura Oncology. MarketBeat recorded 21 mentions for Solid Biosciences and 5 mentions for Kura Oncology. Solid Biosciences' average media sentiment score of 0.87 beat Kura Oncology's score of 0.30 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 9 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySolid Biosciences beats Kura Oncology on 11 of the 17 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$234.55M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-1.9030.1126.4618.82Price / Sales28.99412.67457.0180.76Price / CashN/A183.5344.0437.47Price / Book0.923.567.634.64Net Income-$96.01M-$71.72M$3.18B$245.69M7 Day Performance43.42%-2.45%-1.82%-2.63%1 Month Performance77.30%0.36%0.22%-2.37%1 Year Performance-42.43%-11.50%17.49%13.65% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences4.081 of 5 stars$5.78-3.7%$15.40+166.4%-42.4%$243.47M$8.09M0.00100Analyst ForecastAnalyst RevisionNews CoverageGap UpKURAKura Oncology4.3925 of 5 stars$8.28flat$27.13+227.6%-58.7%$643.85MN/A-3.51130CRMDCorMedix1.3383 of 5 stars$10.48+0.4%$15.67+49.5%+211.7%$635.93M$60,000.00-12.9430News CoveragePositive NewsABUSArbutus Biopharma1.6623 of 5 stars$3.29-0.3%$5.50+67.2%+18.9%$623.42M$18.14M-7.6590PHARPharming Group2.9343 of 5 stars$9.13+3.2%$27.00+195.7%-19.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.6069 of 5 stars$5.05-0.8%$16.67+230.0%-61.7%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5393 of 5 stars$8.36+1.1%$18.71+123.9%-25.6%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeRAPPRapport Therapeutics1.8127 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/AUpcoming EarningsSEPNSepterna2.177 of 5 stars$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.954 of 5 stars$1.96-1.0%$7.00+257.1%+34.5%$574.03M$6.22M-3.56190STOKStoke Therapeutics3.7038 of 5 stars$10.68+0.5%$21.29+99.3%+55.4%$565.72M$8.78M-5.09100Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Kura Oncology Competitors CorMedix Competitors Arbutus Biopharma Competitors Pharming Group Competitors Immatics Competitors ORIC Pharmaceuticals Competitors Rapport Therapeutics Competitors Septerna Competitors Precigen Competitors Stoke Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLDB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLDB Stock Alerts